Rice University researchers in Houston used the foundation of CRISPR/Cas9 technology to develop “drive-and-process” arrays, or DAP for short. The name may be simple, but the technology is complex and could be as groundbreaking as its predecessor. DAP is a mechanism that enables the editing of multiple DNA sites – rather than one at a time – to comprehensively reverse polygenic diseases resulting from multiple genetic predispositions.
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.
Ansa Biotechnologies, a California-based start-up focused on updating DNA synthesis technologies, is advancing toward the launch of a customizable DNA synthesis service, stemming from the development of a novel synthesis method.
Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.
Researchers in Singapore developed the world’s largest and highest-resolution atlas of gastric cancer.
Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.
The mission of new startup Colossal, which has raised $15 million to date, is to genetically reengineer a cold-resistant elephant with all the core biological traits of the extinct woolly mammoth.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.